This database contains 168 studies, archived under the term: "adverse effects"
Click here to filter this large number of results.
Safety and tolerability of rivastigmine capsule with memantine in patients with probable Alzheimer’s disease: a 26-week, open-label, prospective trial (Study ENA713B US32)
Olin, Jason T.,
Bhatnagar, Vinod,
Reyes, Patricio,
Koumaras, Barbara,
Meng, Xiangyi,
Brannan, Stephen
Objective: Rivastigmine, a dual cholinesterase inhibitor (ChEI), is widely approved for the symptomatic treatment of both mild-to-moderate Alzheimer’s disease (AD) and Parkinson’s disease dementia. Orally administered ChEIs may be associated with gastrointestinal (GI) side effects and add-on therapy with memantine, an N-methyl-d-aspartate receptor antagonist, approved for moderate-to-severe AD, may ameliorate such side effects. This was […]
Long-term safety and efficacy of donepezil in patients with severe Alzheimer’s disease: results from a 52-week, open-label, multicenter, extension study in Japan
Homma, Akira,
Imai, Yukimichi,
Tago, Hisao,
Asada, Takashi,
Shigeta, Masahiro,
Iwamoto, Toshihiko,
Takita, Masashi,
Arimoto, Itaru,
Koma, Hiroshi,
Takase, Takao,
Ohbayashi, Toshio
Background/aims: A 6-month, randomized, double-blind, placebo-controlled study was extended to evaluate long-term safety and efficacy of donepezil in community-dwelling Japanese patients with severe Alzheimer’s disease (AD).; Methods: 189 patients were enrolled from the double-blind study into a 52-week, open-label extension study. After a 2- to 8-week washout, donepezil was escalated within 6 weeks to 10 […]
Lithium trial in Alzheimer’s disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study
Hampel, Harald,
Ewers, Michael,
Bürger, Katharina,
Annas, Peter,
Mörtberg, Anette,
Bogstedt, Anna,
Frölich, Lutz,
Schröder, Johannes,
Schönknecht, Peter,
Riepe, Matthias W.,
Kraft, Inga,
Gasser, Thomas,
Leyhe, Thomas,
Möller, Hans-Jürgen,
Kurz, Alexander,
Basun, Hans
Objective: Lithium, a first-line drug for the treatment of bipolar depression, has recently been shown to regulate glycogen synthase kinase-3 (GSK-3), a kinase that is involved in the phosphorylation of the tau protein. Since hyperphosphorylation of tau is a core pathological feature in Alzheimer’s disease, lithium-induced inhibition of GSK-3 activity may have therapeutic effects in […]
A randomized double-blind trial of the effects of hormone therapy on delayed verbal recall in older women
Tierney, Mary C.,
Oh, Paul,
Moineddin, Rahim,
Greenblatt, Ellen M.,
Snow, W. Gary,
Fisher, Rory H.,
Iazzetta, John,
Hyslop, Peter St George,
MacLusky, Neil J.
We examined whether estradiol and norethindrone hormone therapy (HT) prevented decline in delayed verbal recall in older women with normal to mildly impaired memory functioning. This was a 2-year, randomized, double-blind, placebo-controlled trial of 142 women aged 61-87, randomly assigned to receive 1 mg 17-beta estradiol daily and 0.35 mg norethindrone 3 days/week or daily […]
Rosiglitazone monotherapy in mild-to-moderate Alzheimer’s disease: results from a randomized, double-blind, placebo-controlled phase III study
Gold, Michael,
Alderton, Claire,
Zvartau-Hind, Marina,
Egginton, Sally,
Saunders, Ann M.,
Irizarry, Michael,
Craft, Suzanne,
Landreth, Gary,
Linnamägi, Ulla,
Sawchak, Sharon
Background/aims: A phase II study of the peroxisome proliferator-activated receptor-γ agonist rosiglitazone extended release (RSG XR) in mild-to-moderate Alzheimer’s disease (AD) detected a treatment benefit to cognition in apolipoprotein E(APOE)-ε4-negative subjects. The current phase III study with prospective stratification by APOE genotype was conducted to confirm the efficacy and safety of RSG XR in mild-to-moderate […]
Safety and efficacy of galantamine (Reminyl) in severe Alzheimer’s disease (the SERAD study): a randomised, placebo-controlled, double-blind trial
Burns, Alistair,
Bernabei, Roberto,
Bullock, Roger,
Cruz Jentoft, Alfonso J.,
Frölich, Lutz,
Hock, Christoph,
Raivio, Minna,
Triau, Eric,
Vandewoude, Maurits,
Wimo, Anders,
Came, Elizabeth,
Van Baelen, Bart,
Hammond, Gerry L.,
van Oene, Joop C.,
Schwalen, Susanne
Background: The efficacy of galantamine has been shown in patients with mild, moderate, and advanced moderate Alzheimer’s disease (AD). Here we report its efficacy in patients with severe AD.; Methods: Between December, 2003, and March, 2007, patients aged 84 (SD 6) years with severe AD (mini-mental state examination [MMSE] score 5-12 points), in a nursing […]
Safety and tolerability of donepezil in mild cognitive impairment: open-label extension study
Doody, Rachelle S.,
Ferris, Steven,
Salloway, Stephen,
Yijun, Sun,
Goldman, Robert,
Yikang, Xu,
Gao, Jeff,
Murthy, Anita K.
Following a 48-week, double-blind, randomized, placebo-controlled trial of donepezil in 821 patients with amnestic mild cognitive impairment (aMCI), safety and tolerability of donepezil (10 mg) were further evaluated in a 28-week extension study. Of 499 participants who completed the double-blind phase, 145 enrolled in the open-label study. Adverse events (AEs) were recorded throughout. Overall, 57.4% […]
Safety/Tolerability and efficacy of rivastigmine in taiwanese patients with Alzheimer’s disease: a prospective post-marketing surveillance study
Chiu, Pai-Yi,
Dai, Dao-En,
Hsu, Hai-Pei,
Lee, Chao,
Lin, Juei-Jueng,
Kuo, Hung-Chou,
Huang, Ying-Chih,
Liu, Yung-Chang,
Tsai, Ching-Piao
Background and Objectives: Rivastigmine is approved for the symptomatic treatment of mild to moderate dementia in patients with Alzheimer’s disease. The drug was launched in Taiwan in 2000. The primary objective of this post-marketing surveillance (PMS) study was to describe the safety/tolerability of treatment with rivastigmine capsules in patients with Alzheimer’s disease. The secondary objectives […]